Use of an anti-IL-17RB antibody, or antigen-binding fragment or composition thereof

CN122396504APending Publication Date: 2026-07-14SINOMAB BIOSCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380104593.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-12-05
Publication Date
2026-07-14

AI Technical Summary

Technical Problem

The prior art is difficult to effectively treat silk polyprotein (FLG)-related diseases, especially atopic dermatitis, and traditional treatment methods have side effects and poor efficacy.

Method used

An anti-IL-17RB antibody was developed to inhibit the IL-17RB signaling pathway by specifically binding to IL-17RB, reverse Th2-driven downregulation of FLG expression, reduce the secretion of ILC2 population and inflammatory cells in the lymph nodes, thereby restoring skin barrier function.

Benefits of technology

Anti-IL-17RB antibodies significantly reduce the symptoms of atopic dermatitis, improve skin pathology, restore the expression of silencing protein, and are better than existing drugs such as uppatinib, especially in reducing itching and improving skin health.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000015_0000
    Figure 00000015_0000
  • Figure 00000015_0001
    Figure 00000015_0001
  • Figure 00000015_0002
    Figure 00000015_0002
Patent Text Reader

Abstract

The present application discloses an isolated anti-IL-17RB antibody, or an antigen binding fragment thereof, or a pharmaceutical composition comprising the same, for treating FLG-associated diseases, which is capable of reversing the down-regulation of Th2-driven filaggrin expression, and thus can effectively treat FLG-associated diseases.
Need to check novelty before this filing date? Find Prior Art